Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBK | Q96KB5 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 8/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 3/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9882240 | 0.86 | PIM1 (0.49) | PRKCQPRKCDPIM1 | |
| SCHEMBL9883376 | 0.83 | PIM1 (0.46) | PRKCQPRKCDPRKCAPIM1 | |
| SCHEMBL9882269 | 0.83 | PIM1 (0.46) | PRKCQPRKCDPRKCAPIM1 | |
| SCHEMBL9882260 | 0.83 | PRKCQ (0.46) | PRKCQPRKCDPRKCAPIM1 | |
| SCHEMBL9882249 | 0.83 | PIM1 (0.53) | PRKCQPRKCDPRKCAPIM1KDM4E | |
| SCHEMBL9882248 | 0.82 | PIM1 (0.42) | PRKCQPRKCDPRKCAPIM1KDM4E | |
| SCHEMBL9882213 | 0.82 | PRKCQ (0.46) | PRKCQPRKCDPRKCAPIM1 | |
| SCHEMBL9882216 | 0.81 | PRKCQ (0.54) | PRKCQPRKCDPRKCAPIM1 | |
| SCHEMBL9882283 | 0.81 | PRKCQ (0.41) | PRKCQPRKCDPRKCAPIM1 | |
| SCHEMBL9882265 | 0.81 | PRKCQ (0.41) | PRKCQPRKCDPRKCAPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | PBK 768/4885PRKCQ 51/4885PRKCD 144/4885 |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | PBK 768/4885PRKCQ 51/4885PRKCD 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.